Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Drug-conjugated antibodies for the treatment of cancer.

Lambert JM.

Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review.

2.

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Lambert JM, Morris CQ.

Adv Ther. 2017 May;34(5):1015-1035. doi: 10.1007/s12325-017-0519-6. Epub 2017 Mar 30. Review.

3.

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.

Jerjian TV, Glode AE, Thompson LA, O'Bryant CL.

Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687. Review.

PMID:
26799352
4.

Strategies and challenges for the next generation of antibody-drug conjugates.

Beck A, Goetsch L, Dumontet C, Corvaïa N.

Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. Review.

PMID:
28303026
5.

Antibody-targeted drugs and drug resistance--challenges and solutions.

Shefet-Carasso L, Benhar I.

Drug Resist Updat. 2015 Jan;18:36-46. doi: 10.1016/j.drup.2014.11.001. Epub 2014 Nov 21. Review.

PMID:
25476546
6.

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.

Beerli RR, Hell T, Merkel AS, Grawunder U.

PLoS One. 2015 Jul 1;10(7):e0131177. doi: 10.1371/journal.pone.0131177. eCollection 2015.

7.

Linked-in: design and efficacy of antibody drug conjugates in oncology.

Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK.

Oncotarget. 2013 Mar;4(3):397-412.

8.

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

Mehta A, Forero-Torres A.

Curr Oncol Rep. 2015 Sep;17(9):41. doi: 10.1007/s11912-015-0466-9. Review.

PMID:
26194424
9.

Antibody-drug conjugates: present and future.

Beck A, Reichert JM.

MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.

PMID:
24423577
10.

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.

Corrigan PA, Cicci TA, Auten JJ, Lowe DK.

Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Review.

PMID:
25082874
11.

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.

Beck A, Lambert J, Sun M, Lin K.

MAbs. 2012 Nov-Dec;4(6):637-47. doi: 10.4161/mabs.21697. Epub 2012 Aug 22.

12.

The next generation of antibody drug conjugates.

Mack F, Ritchie M, Sapra P.

Semin Oncol. 2014 Oct;41(5):637-52. doi: 10.1053/j.seminoncol.2014.08.001. Epub 2014 Aug 12. Review.

PMID:
25440608
13.

Antibody-drug conjugates--an emerging class of cancer treatment.

Diamantis N, Banerji U.

Br J Cancer. 2016 Feb 16;114(4):362-7. doi: 10.1038/bjc.2015.435. Epub 2016 Jan 7. Review.

14.

Developments in the use of antibody-drug conjugates.

Burris HA.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e99. Review.

15.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
16.

Antibody-drug conjugate (ADC) clinical pipeline: a review.

Sassoon I, Blanc V.

Methods Mol Biol. 2013;1045:1-27. doi: 10.1007/978-1-62703-541-5_1. Review.

PMID:
23913138
17.

Current methods for the synthesis of homogeneous antibody-drug conjugates.

Sochaj AM, Świderska KW, Otlewski J.

Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):775-84. doi: 10.1016/j.biotechadv.2015.05.001. Epub 2015 May 14. Review.

18.

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.

Sapra P, Betts A, Boni J.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):541-55. doi: 10.1586/17512433.2013.827405. Epub 2013 Aug 26. Review.

PMID:
23978126
19.

Antibody-drug conjugates as novel anti-cancer chemotherapeutics.

Peters C, Brown S.

Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089. Review.

20.

Antibody drug conjugates.

Bakhtiar R.

Biotechnol Lett. 2016 Oct;38(10):1655-64. doi: 10.1007/s10529-016-2160-x. Epub 2016 Jun 22. Review.

PMID:
27334710

Supplemental Content

Support Center